Medicine Name:
Jalra-M 50mg/850mg Tablet
Required Status:
Prescription Required
Type of Selection:
10 tablets in 1 strip
Manufacturer:
USV Ltd
Salt:
Metformin (850mg) + Vildagliptin (50mg),
MRP:
₹277.56
Uses:
Type 2 diabetes mellitus,
Alternate Medicines:
Vilact M 850 Tablet,Torglip M 50/850 Tablet,Encelin M 50/850 Tablet,Vildaprime M 850mg/50mg Tablet,Vildamac M 50/850 Tablet,
Side Effects:
Nausea,Vomiting,Diarrhea,Stomach pain,Loss of appetite,Dizziness,Headache,Trembling,Metallic taste,Hypoglycemia (low blood glucose level),
How to Use:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jalra-M 50mg/850mg Tablet is to be taken with food.
Chemical Class:
Not Listed
Habit Forming:
No
Therapeutic Class:
ANTI DIABETIC
Action Class:
Not Listed
. Please note, this information is for educational purposes only and not intended as medical advice.
Jalra-M 50mg/850mg Tablet – Comprehensive Medication Guide
Jalra-M 50mg/850mg Tablet is a prescription medication used in the management of Type 2 diabetes mellitus. This medication contains two active ingredients – Metformin (850mg) and Vildagliptin (50mg). Metformin is a biguanide that works by decreasing glucose production in the liver and improving insulin sensitivity in the muscles. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps regulate blood sugar levels by increasing insulin production in response to food intake.
Pharmacological Properties:
Metformin and Vildagliptin work in synergy to control blood glucose levels in patients with Type 2 diabetes. Metformin decreases the amount of glucose produced by the liver, while Vildagliptin enhances insulin secretion in response to meals. This dual mechanism of action helps improve glycemic control and reduces the risk of complications associated with diabetes.
Indications:
Jalra-M 50mg/850mg Tablet is indicated for the treatment of Type 2 diabetes mellitus in adults. It is prescribed to help control blood sugar levels and prevent complications related to diabetes, such as kidney damage, nerve problems, and vision loss.
Contraindications:
Jalra-M 50mg/850mg Tablet is contraindicated in patients with a history of hypersensitivity to Metformin, Vildagliptin, or any other components of the medication. It should not be used in patients with severe kidney impairment, liver disease, or metabolic acidosis.
Dosage and Administration:
The recommended dose of Jalra-M 50mg/850mg Tablet is determined by the physician based on the individual’s medical condition and response to treatment. It is typically taken twice daily with meals to reduce the risk of gastrointestinal side effects. The tablet should be swallowed whole with a glass of water and should not be chewed, crushed, or broken.
Side Effects:
Common side effects of Jalra-M 50mg/850mg Tablet may include nausea, vomiting, diarrhea, stomach pain, loss of appetite, dizziness, headache, trembling, metallic taste in the mouth, and hypoglycemia (low blood sugar levels). It is important to inform your healthcare provider if any of these side effects persist or worsen over time.
Drug Interactions:
Jalra-M 50mg/850mg Tablet may interact with certain medications, such as insulin, other antidiabetic agents, diuretics, corticosteroids, and certain antibiotics. These interactions can affect the efficacy of the medication or increase the risk of adverse effects. It is essential to inform your doctor about all the medications you are currently taking before starting Jalra-M.
Patient Counseling:
Patients taking Jalra-M 50mg/850mg Tablet should be advised to maintain a healthy lifestyle, including a balanced diet and regular physical activity. Monitoring blood sugar levels as directed by the healthcare provider is crucial for effective diabetes management. It is also important to stay hydrated and avoid excessive alcohol consumption while on this medication.
Clinical Evidence:
Clinical studies have demonstrated the efficacy and safety of Jalra-M 50mg/850mg Tablet in managing Type 2 diabetes mellitus. These trials have shown that the combination of Metformin and Vildagliptin provides better control of blood sugar levels compared to either medication alone. Additionally, Jalra-M has been associated with a lower risk of hypoglycemia and weight gain in diabetic patients.
Frequently Asked Questions (FAQs):
Q: Can Jalra-M be used in the treatment of Type 1 diabetes?
A: No, Jalra-M 50mg/850mg Tablet is specifically approved for the treatment of Type 2 diabetes mellitus and should not be used in patients with Type 1 diabetes.
Q: How long does it take for Jalra-M to start working?
A: Jalra-M may start to lower blood sugar levels within a few days of starting the medication. However, it may take several weeks to see the full therapeutic effects.
Q: What should I do if I miss a dose of Jalra-M?
A: If you miss a dose of Jalra-M, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one.
Q: Can Jalra-M cause weight gain?
A: Unlike some antidiabetic medications, Jalra-M is not associated with significant weight gain. In fact, it may help promote weight loss in certain individuals by improving glycemic control.
Q: Is it safe to drive or operate machinery while taking Jalra-M?
A: Jalra-M may cause dizziness or drowsiness in some patients. It is advisable to avoid driving or operating heavy machinery until you know how this medication affects you.
Q: Can I drink alcohol while on Jalra-M treatment?
A: Alcohol consumption can affect blood sugar levels and may interfere with the action of Jalra-M. It is recommended to limit alcohol intake and consult your healthcare provider for personalized advice.
Q: What measures can I take to reduce the risk of gastrointestinal side effects while on Jalra-M?
A: To reduce the risk of gastrointestinal side effects like nausea and diarrhea, it is recommended to take Jalra-M with meals and stay hydrated. Eating smaller, more frequent meals may also help alleviate these symptoms.
Q: How long should I continue taking Jalra-M?
A: The duration of Jalra-M treatment is determined by your healthcare provider based on your individual response to the medication and overall health condition. It is essential to follow your doctor’s recommendations and not discontinue the medication without consulting them.
Q: Is Jalra-M habit-forming?
A: Jalra-M is not habit-forming and does not have addictive properties. However, it is essential to take this medication as prescribed by your doctor to achieve optimal treatment outcomes.
In conclusion, Jalra-M 50mg/850mg Tablet is a valuable medication in the management of Type 2 diabetes mellitus. By understanding its active ingredients, pharmacological properties, indications, contraindications, dosage, side effects, drug interactions, patient counseling, and clinical evidence, patients can achieve better control of their condition with the guidance of healthcare professionals. Remember that this information is for educational purposes only and should not replace personalized medical advice from a qualified healthcare provider.
